Shots:
- Bayer has entered into an exclusive global license agreement & collaboration with Kumquat Biosciences to develop and commercialize its KRAS G12D inhibitor
- Kumquat will initiate & complete the P-Ia study following FDA’s IND clearance in Jul 2025, while Bayer handles further development & commercialization, with Kumquat holding an exclusive option to negotiate US profit-loss sharing
- As per the deal, Kumquat will receive ~$1.3B in total, incl. upfront, clinical, & commercial milestone payments, along with net sales-based tiered royalties
Ref: Bayer | Image: Bayer and Kumquat Biosciences | Press Release
Related News:- Bayer Reports EC’s Approval of Nubeqa for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
